Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.

Abstract:

:Malignant astrocytomas are infiltrative and incurable brain tumors. Despite profound therapeutic implications, the identity of the cell (or cells) of origin has not been rigorously determined. We previously reported mouse models based on conditional inactivation of the human astrocytoma-relevant tumor suppressors p53, Nf1, and Pten, wherein through somatic loss of heterozygosity, mutant mice develop tumors with 100% penetrance. In the present study, we show that tumor suppressor inactivation in neural stem/progenitor cells is both necessary and sufficient to induce astrocytoma formation. We demonstrate in vivo that transformed cells and their progeny undergo infiltration and multilineage differentiation during tumorigenesis. Tumor suppressor heterozygous neural stem/progenitor cultures from presymptomatic mice show aberrant growth advantage and altered differentiation, thus identifying a pretumorigenic cell population.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Alcantara Llaguno S,Chen J,Kwon CH,Jackson EL,Li Y,Burns DK,Alvarez-Buylla A,Parada LF

doi

10.1016/j.ccr.2008.12.006

subject

Has Abstract

pub_date

2009-01-06 00:00:00

pages

45-56

issue

1

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(08)00409-1

journal_volume

15

pub_type

杂志文章
  • Optimal gene expression analysis by microarrays.

    abstract::DNA microarrays make possible the rapid and comprehensive assessment of the transcriptional activity of a cell, and as such have proven valuable in assessing the molecular contributors to biological processes and in the classification of human cancers. The major challenge in using this technology is the analysis of it...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00181-2

    authors: Miller LD,Long PM,Wong L,Mukherjee S,McShane LM,Liu ET

    更新日期:2002-11-01 00:00:00

  • Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

    abstract::The proapoptotic death receptor DR5 has been studied extensively in cancer cells, but its action in the tumor microenvironment is not well defined. Here, we uncover a role for DR5 signaling in tumor endothelial cells (ECs). We detected DR5 expression in ECs within tumors but not normal tissues. Treatment of tumor-bear...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.05.014

    authors: Wilson NS,Yang A,Yang B,Couto S,Stern H,Gogineni A,Pitti R,Marsters S,Weimer RM,Singh M,Ashkenazi A

    更新日期:2012-07-10 00:00:00

  • High-throughput Phenotyping of Lung Cancer Somatic Mutations.

    abstract::Recent genome sequencing efforts have identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood. Here we characterize 194 somatic mutations identified in primary lung adenocarcinomas. We present an expression-based variant-impact phenotyping (eVIP) method ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.06.022

    authors: Berger AH,Brooks AN,Wu X,Shrestha Y,Chouinard C,Piccioni F,Bagul M,Kamburov A,Imielinski M,Hogstrom L,Zhu C,Yang X,Pantel S,Sakai R,Watson J,Kaplan N,Campbell JD,Singh S,Root DE,Narayan R,Natoli T,Lahr DL,Tiro

    更新日期:2016-08-08 00:00:00

  • Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

    abstract::From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells. Expression of this mitochondrial protease that has structural similarity to the cytoplasmic proteosome is increased in leukemic cells from approximately half of all patients ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.05.004

    authors: Cole A,Wang Z,Coyaud E,Voisin V,Gronda M,Jitkova Y,Mattson R,Hurren R,Babovic S,Maclean N,Restall I,Wang X,Jeyaraju DV,Sukhai MA,Prabha S,Bashir S,Ramakrishnan A,Leung E,Qia YH,Zhang N,Combes KR,Ketela T,Lin F

    更新日期:2015-06-08 00:00:00

  • The sum is greater than the FGFR1 partner.

    abstract::Cancer-associated chromosomal translocations create chimeric oncoproteins that contribute to aberrant growth by dominant or dominant negative mechanisms. Interestingly, genes such as MLL, RARA, and EWS are fused to multiple partners. This molecular promiscuity can provide important functional information, as specific ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(04)00060-1

    authors: Braun BS,Shannon K

    更新日期:2004-03-01 00:00:00

  • Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

    abstract::We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the pre...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.11.004

    authors: Packer LM,Rana S,Hayward R,O'Hare T,Eide CA,Rebocho A,Heidorn S,Zabriskie MS,Niculescu-Duvaz I,Druker BJ,Springer C,Marais R

    更新日期:2011-12-13 00:00:00

  • In the pursuit of complexity: systems medicine in cancer biology.

    abstract::Adler et al., in a paper appearing in Nature Genetics, exploited the intersect of genetic information from expression profiles with that from array comparative genomic hybridization in human breast cancers to identify genes that may induce the transcription of the prognostic "wound response" expression signature. The ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2006.03.026

    authors: Liu ET,Kuznetsov VA,Miller LD

    更新日期:2006-04-01 00:00:00

  • Inactivation of E2F3 results in centrosome amplification.

    abstract::The E2F family of transcription factors is critical for the control of cell cycle progression. We now show that the specific inactivation of E2F3 in mouse embryo fibroblasts (MEFs) results in a disruption of the centrosome duplication cycle. Loss of E2F3, but not E2F1, E2F2, E2F4, or E2F5 results in unregulated cyclin...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(03)00083-7

    authors: Saavedra HI,Maiti B,Timmers C,Altura R,Tokuyama Y,Fukasawa K,Leone G

    更新日期:2003-04-01 00:00:00

  • Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

    abstract::Mdmx is a critical negative regulator of the p53 pathway that is stoichiometrically limiting in some tissues. Posttranslational modification and degradation of Mdmx after DNA damage have been proposed to be essential for p53 activation. We tested this model in vivo, where critical stoichiometric relationships are pres...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.05.008

    authors: Wang YV,Leblanc M,Wade M,Jochemsen AG,Wahl GM

    更新日期:2009-07-07 00:00:00

  • Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.

    abstract::Obesity is a leading risk factor for cancer. However, understanding the crosstalk between adipocytes and tumor cells in vivo, independently of dietary contributions, is a major gap in the field. Here we used a prostate cancer (PCa) mouse model in which the signaling adaptor p62/Sqstm1 is selectively inactivated in adi...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.03.001

    authors: Huang J,Duran A,Reina-Campos M,Valencia T,Castilla EA,Müller TD,Tschöp MH,Moscat J,Diaz-Meco MT

    更新日期:2018-04-09 00:00:00

  • Cancer therapeutics in yeast.

    abstract::The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action. ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00160-5

    authors: Bjornsti MA

    更新日期:2002-10-01 00:00:00

  • Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

    abstract::To identify regulatory drivers of prostate cancer malignancy, we have assembled genome-wide regulatory networks (interactomes) for human and mouse prostate cancer from expression profiles of human tumors and of genetically engineered mouse models, respectively. Cross-species computational analysis of these interactome...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2014.03.017

    authors: Aytes A,Mitrofanova A,Lefebvre C,Alvarez MJ,Castillo-Martin M,Zheng T,Eastham JA,Gopalan A,Pienta KJ,Shen MM,Califano A,Abate-Shen C

    更新日期:2014-05-12 00:00:00

  • Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.

    abstract::Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.10.008

    authors: Zhao W,Li J,Chen MM,Luo Y,Ju Z,Nesser NK,Johnson-Camacho K,Boniface CT,Lawrence Y,Pande NT,Davies MA,Herlyn M,Muranen T,Zervantonakis IK,von Euw E,Schultz A,Kumar SV,Korkut A,Spellman PT,Akbani R,Slamon DJ,Gray

    更新日期:2020-12-14 00:00:00

  • Stressing Out about Cancer Immunotherapy.

    abstract::Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccell.2019.10.013

    authors: He XY,Ng D,Van Aelst L,Egeblad M

    更新日期:2019-11-11 00:00:00

  • ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

    abstract::Here, we show that tumor ADORA1 deletion suppresses cell growth in human melanoma cell lines in vitro and tumor development in vivo in immune-deficient xenografts. However, this deletion induces the upregulation of PD-L1 levels, which inactivates cocultured T cells in vitro, compromises anti-tumor immunity in vivo, an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.02.006

    authors: Liu H,Kuang X,Zhang Y,Ye Y,Li J,Liang L,Xie Z,Weng L,Guo J,Li H,Ma F,Chen X,Zhao S,Su J,Yang N,Fang F,Xie Y,Tao J,Zhang J,Chen M,Peng C,Sun L,Zhang X,Liu J,Han L,Xu X,Hung MC,Chen X

    更新日期:2020-03-16 00:00:00

  • PI3K regulatory subunits lose control in cancer.

    abstract::The PI3K signaling axis is frequently activated in cancer resulting from inactivation of its negative regulator PTEN or activating mutations of the p110alpha catalytic subunit of PI3K. In this issue of Cancer Cell, Jaiswal et al. report that mutations in the p85alpha regulatory subunit of PI3K can also activate this p...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2009.11.017

    authors: Berenjeno IM,Vanhaesebroeck B

    更新日期:2009-12-08 00:00:00

  • Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

    abstract::PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2014.08.017

    authors: Cheung LW,Yu S,Zhang D,Li J,Ng PK,Panupinthu N,Mitra S,Ju Z,Yu Q,Liang H,Hawke DH,Lu Y,Broaddus RR,Mills GB

    更新日期:2014-10-13 00:00:00

  • NAD(+) supplementation as a novel approach to cURIng HCC?

    abstract::In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD(+)) metabolism. The results suggest that ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2014.11.011

    authors: Mederacke I,Schwabe RF

    更新日期:2014-12-08 00:00:00

  • Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.

    abstract::Polymorphonuclear neutrophils (PMNs) are largely considered to foster cancer development despite wielding an arsenal of cytotoxic agents. Using a mouse model of PTEN-deficient uterine cancer, we describe a surprising inhibitory role for PMNs in epithelial carcinogenesis. By inducing tumor cell detachment from the base...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.11.005

    authors: Blaisdell A,Crequer A,Columbus D,Daikoku T,Mittal K,Dey SK,Erlebacher A

    更新日期:2015-12-14 00:00:00

  • Wild-type RAS: keeping mutant RAS in CHK.

    abstract::Mutant RAS-driven tumorigenesis was thought for decades to arise independently of wild-type RAS isoforms, but recent evidence indicates wild-type isoforms are involved. In this issue of Cancer Cell, Grabocka and colleagues report how the loss of wild-type RAS alters oncogenic signaling and dampens the DNA-damage respo...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2014.01.029

    authors: Anastassiadis T,Brown EJ

    更新日期:2014-02-10 00:00:00

  • Cancer Patients and Risk of Mortality for COVID-19.

    abstract::Two recent Lancet and Lancet Oncology papers report that cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have higher mortality rates. Common independent factors associated with increased risk of death were older age, history of smoking status, number of comorbidities, more a...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.07.006

    authors: Curigliano G

    更新日期:2020-08-10 00:00:00

  • Reinforcing suppression using regulators: a new link between STAT3, IL-23, and Tregs in tumor immunosuppression.

    abstract::STAT3 plays many roles in tumorigenesis. In this issue of Cancer Cell, Kortylewski et al. show that in the tumor microenvironment, STAT3 enhances the expression of the protumor cytokine IL-23 in macrophages but inhibits the antitumor cytokine IL-12 in dendritic cells. STAT3 also mediates IL-23's effect of activating t...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2009.01.008

    authors: Stewart CA,Trinchieri G

    更新日期:2009-02-03 00:00:00

  • Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.

    abstract::The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.04.026

    authors: Nikolaou K,Tsagaratou A,Eftychi C,Kollias G,Mosialos G,Talianidis I

    更新日期:2012-06-12 00:00:00

  • Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.

    abstract::Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier in early cancer development, at least in part, via an oncogene-evoked DNA damage response (DDR). In contrast, Myc activation-although producing a DDR as well-is known to primarily elicit an apoptotic countermeasure. Using the Emu-my...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.12.043

    authors: Reimann M,Lee S,Loddenkemper C,Dörr JR,Tabor V,Aichele P,Stein H,Dörken B,Jenuwein T,Schmitt CA

    更新日期:2010-03-16 00:00:00

  • Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

    abstract::The metastatic process of colorectal cancer (CRC) is not fully understood and effective therapies are lacking. We show that activation of NOTCH1 signaling in the murine intestinal epithelium leads to highly penetrant metastasis (100% metastasis; with >80% liver metastases) in KrasG12D-driven serrated cancer. Transcrip...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.08.003

    authors: Jackstadt R,van Hooff SR,Leach JD,Cortes-Lavaud X,Lohuis JO,Ridgway RA,Wouters VM,Roper J,Kendall TJ,Roxburgh CS,Horgan PG,Nixon C,Nourse C,Gunzer M,Clark W,Hedley A,Yilmaz OH,Rashid M,Bailey P,Biankin AV,Campbell

    更新日期:2019-09-16 00:00:00

  • The Two Faces of NF-κB Signaling in Cancer Development and Therapy.

    abstract::Constitutive activation of NF-κB signaling can promote oncogenesis, providing a rationale for anticancer strategies that inhibit NF-κB signaling. Two recent publications in Genes & Development provide evidence that, in contexts where prosurvival signals derive from other oncogenes, NF-κB activity instead enhances sens...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2011.10.026

    authors: Klein U,Ghosh S

    更新日期:2011-11-15 00:00:00

  • EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

    abstract::The EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and targeted by somatic mutations in B cell lymphomas. Here, we find that EZH2 deletion or pharmacologic inhibition suppresses GC formation and functions. EZH2 represses proliferation checkpoint genes and helps establish bivalent ch...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.04.011

    authors: Béguelin W,Popovic R,Teater M,Jiang Y,Bunting KL,Rosen M,Shen H,Yang SN,Wang L,Ezponda T,Martinez-Garcia E,Zhang H,Zheng Y,Verma SK,McCabe MT,Ott HM,Van Aller GS,Kruger RG,Liu Y,McHugh CF,Scott DW,Chung YR,Kel

    更新日期:2013-05-13 00:00:00

  • Kidney cancer: now available in a new flavor.

    abstract::The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2008.11.005

    authors: Kaelin WG Jr

    更新日期:2008-12-09 00:00:00

  • Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

    abstract::Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin. To circumvent this, we analyzed the function of EWS/FLI in Ewing's sarcoma itself. By combining retroviral-mediated RNA interference with reexpression stud...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.04.004

    authors: Smith R,Owen LA,Trem DJ,Wong JS,Whangbo JS,Golub TR,Lessnick SL

    更新日期:2006-05-01 00:00:00

  • HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.

    abstract::HIF-2alpha promotes von Hippel-Lindau (VHL)-deficient renal clear cell carcinoma (RCC) tumorigenesis, while HIF-1alpha inhibits RCC growth. As HIF-1alpha antagonizes c-Myc function, we hypothesized that HIF-2alpha might enhance c-Myc activity. We demonstrate here that HIF-2alpha promotes cell-cycle progression in hypo...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.02.006

    authors: Gordan JD,Bertout JA,Hu CJ,Diehl JA,Simon MC

    更新日期:2007-04-01 00:00:00